---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-021064"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T03:45:39.072762+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology Q2 2022: $122M cash; preclinical ovarian data shows onvansertib + olaparib survival benefit

## Summary
- Cash, equivalents, and short-term investments of ~$122M as of June 30, 2022; net cash used in Q2 2022 was $6.7M, up from $4.3M in Q2 2021.
- R&D expenses rose to $7.45M from $4.12M YoY, driven by CMC and clinical pharmacology studies for onvansertib.
- Preclinical ovarian cancer data at AACR: onvansertib + olaparib showed statistically significant survival benefit vs either agent alone in three PDX models.
- Phase 2 mCRPC trial: 75% (15/20) of most dose-dense arm achieved stable disease or partial response at 12 weeks; response correlated with PTEN/MTOR mutations.

## SEC filing metadata
- accession: 0001628280-22-021064
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000162828022021064/0001628280-22-021064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000162828022021064/crdf-20220804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-021064
- JSON: https://secwatch.observer/filing/0001628280-22-021064.json
- Plain text: https://secwatch.observer/filing/0001628280-22-021064.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.